Med Tech companies are facing challenges in commercializing their innovative products and increasingly need to demonstrate clinical utility and economic value to obtain coverage and reimbursement. Providers are assuming greater financial risk for patient care as payers move away from service based reimbursement towards more bundled and population based payments. Electronic health data (medical records, lab information, patient reported outcomes, claims, etc.) are a valuable source of tracking patient outcomes and costs and reporting on quality indicators.
Marianne Laouri, Ph.D. – Specialist Leader Life Sciences Strategy and Operations, Deloitte Consulting LLP
Marianne is a senior health service research professional with over 20 years of experience in across health plans, pharmacy benefits management companies, manufacturers, health policy think tanks, and consulting. During the course of her career, she has led successful health economics and outcomes research teams, and has advised life sciences companies on pricing and payer value strategies. She has held leadership positions in payer organizations with accountability for decisions about coverage of medical technologies ranging from biopharmaceutical products to medical devices and diagnostics. She is well versed in value based pricing methods, benefit design and coverage and reimbursement for medical innovations from both the life sciences companies’ perspective and that of payers. Marianne is highly knowledgeable about CER methods and the implications of CER for life sciences companies, and has published extensively on the subjects of health economics and outcomes research. Marianne has served many clients including: The Center for Medical Technology Policy, Genentech, Novartis, HealthCore, Pathwork Diagnostics, bioTheranostics and Allergan. She received her doctorate from the University of California, Los Angeles, and started her career at RAND.
Glenn H. Snyder – Principal, Lifesciences Strategy and Operations, Deloitte Consulting LLP
Glenn Snyder is a Principal with Deloitte Consulting, LLP. He currently leads Deloitte Consulting’s Medical Technology practice as well as the Industry Eminence Program for Life Sciences and Health Care Consulting. He has been serving the life sciences and healthcare industry as a consultant since 1989 and has been with Deloitte since 1995. Glenn’s expertise is within strategy for the life sciences sector, with deep experience in medical technology, biotech and specialty pharmaceuticals. He has helped clients price products, gain better net reimbursement, articulate product economic value, launch new products, improve market access and rationalize distribution networks. He has also helped clients expand in new/emerging markets and has conducted insightful research and presented on this topic. Glenn has tackled issues across the healthcare value chain over the course of his career, including the payor and provider sectors. Recently, Glenn has helped several life sciences companies navigate changes in the healthcare ecosystem (including those specific to health reform) by modifying their commercial model, and developing tangible growth plans that incorporate maturity aspirations, external pressures and internal pipeline expectations. An eminent speaker and thought leader, Glenn has presented at notable conferences, including CalBIO2012, Bio/Pharma Trade Channel Strategies, BIO International Convention, BayBio, and Analytical and Lifesciences Systems Association. Glenn has also published several articles and whitepapers through Deloitte, Deloitte Review, Pharma Processing, and Future Pharma. Glenn holds a Master of Business Administration in Finance and Strategic Management from the Wharton School of the University of Pennsylvania, a Master of Science in Engineering from the University of Southern California, and a Bachelor of Science in Engineering from Cal Poly, San Luis Obispo. Glenn is an avid mountain biker, and is involved in governing and advisory boards of two educational institutions.
- Jan Hansen, Ph.D – VP Global Health Outcomes, Allergan
- Lynda Gibson – Director, Business Intelligence, Deloitte Consulting LLP
- Anwer Khan – Director, Life Sciences Information Management & Business Analytics, Deloitte Consulting LLP
Breakfast will be served.